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Background: Agents for prophylaxis of hereditary angioedema
(HAE) have been available in the United States for several decades,
but their usefulness is limited by side effects and they cannot be used
at all in some patients. No agents have been available in the United
States to specifically treat acute attacks. HAE types I and II are
associated with low functional levels of C1 inhibitor, and evidence
accumulated over decades suggests that intravenous infusion of C1
inhibitor is useful for terminating angioedema attacks and for
prophylaxis.
Key Points: C1 inhibitor derived from pooled human plasma has
been available for decades in Europe, and 2 preparations have been
recently introduced into the United States. Both have been effica-
cious in carefully controlled double-blind studies. One preparation,
Cinryze, was approved by the U.S. Food & Drug Administration
(FDA) for prophylaxis of HAE attacks in October 2008, and the
second, Berinert, was approved by the FDA for treatment of acute
attacks in October 2009. A third preparation, the recombinant
human C1 inhibitor Rhucin, is completing clinical trials. Although
not yet approved by the FDA, preliminary results made available
suggest that Rhucin, too, is effective in terminating attacks of HAE.
Conclusions: Americans will now have access to effective acute
and prophylactic treatments with C1 inhibitor for hereditary
angioedema.
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Hereditary angioedema (HAE) is an episodic swellingdisorder that involves the subcutaneous tissues of the
extremities or the mucosa of the bowel and occasionally the
tissues of the face, mouth, and pharynx or the genital area.1,2
Attacks most commonly increase in severity for about 1.5
days and then resolve during about the same period of time.
Patients are usually most bothered by the painful abdominal
attacks, which can be very severe and can lead to abdominal
surgery; however, the development of laryngeal angioedema
can lead to asphyxiation and death. HAE types I and II are
caused by mutations in 1 of the 2 gene alleles that code for the
plasma protein C1 inhibitor. This protein was named for its
ability to regulate the activity of the complement protein C1,
but C1 inhibitor has been found to act as a regulator or
inhibitor of the clotting, fibrinolytic, and kinin-generating
systems in plasma as well. It is now believed that comple-
ment is not the major system responsible for HAE attacks,
although the failure of C1 inhibitor to regulate activation of
the complement system in these patients has led to the most
commonly used diagnostic test other than the level or function
of C1 inhibitor itself, the plasma concentration of C4; the level
of the complement protein C4 is almost always low in these
patients. The failure to adequately regulate the kinin system
leads to the unregulated formation of bradykinin, which in turn
leads to angioedema.3
Identification of the elements of the kinin pathway has
led to the development of highly specific therapy; however,
even before this information was available, considerable
progress was made in attempts to provide long-term prophy-
laxis for patients with HAE. Epsilon aminocaproic acid, the
first agent found to be effective in prophylactic treatment of
HAE,4,5 was identified during a random screen of diseases
that may respond to treatment with this agent. Frank and
colleagues at the National Institutes of Health performed a
small double-blind trial that confirmed the effectiveness of
the drug in preventing HAE.6 Over time, it became clear that
epsilon aminocaproic acid, a fibrinolysis inhibitor, has many
side effects that limit its use. A related drug, tranexamic acid,
was developed that is less toxic and has been used with
success in Europe, but it has not been widely used in the
United States.7 Several years after the identification of the
antifibrinolytics as useful in prophylaxis, the androgens were
shown to be effective in the prophylaxis of HAE.8 Their
mechanism of action is still not completely clear, but patients
with HAE are heterozygous for the defective C1 inhibitor
gene allele, and androgens seem to increase synthesis of C1
inhibitor by the normal gene allele. Androgens have proven
very useful, but they are not effective in everyone, cannot be
used in children or pregnant women, and have a great many
side effects that, although generally mild, preclude their use
in some people.9 Furthermore, they regularly induce weight
gain and alterations in blood lipids that may predispose
patients taking them for decades to atherosclerosis and car-
diovascular disease.10 None of these prophylactic drugs are
effective as acute therapy and it is clear that new, more-
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specific agents are needed. Fresh-frozen plasma has been
widely used in acute attacks.11 However, it rarely can in-
crease angioedema during attacks because it supplies the
precursor proteins for kinin generation.
DEVELOPMENT OF C1 INHIBITOR THERAPY
In 1963, Donaldson and Evans reported that HAE
patients have a specific inherited defect in the plasma protein
C1 inhibitor.12 Patients with type I HAE were later shown to
have low levels of this protein because its synthesis or
secretion was prevented by mutations in one of the gene
alleles; in general, patients with type II HAE have a defect in
a gene allele that results in secretion of a nonfunctioning
protein.13 Infusion of the missing functional protein C1 in-
hibitor was an obvious approach to specific therapy. Three
groups, the American Red Cross, the Dutch Red Cross, and
the Behring Company in Germany all set out to purify C1
inhibitor from plasma. All of these groups already had facil-
ities for collecting and pooling plasma from thousands of
donors and purifying individual plasma proteins because all
were suppliers of gamma globulin for patient use. The au-
thor’s own group had access to the American Red Cross
preparation and in 1980 reported that C1 inhibitor infusion
raised plasma C1 inhibitor levels as expected in 8 patients
and, as a consequence of its action in inhibiting activated C1,
also raised the levels of serum C4.14 We reported that this
treatment terminated angioedema attacks in 5 of our patients
who were having attacks at the time of their infusion.14 At
about the same time, the Dutch Red Cross developed a
preparation of C1 inhibitor, and Agostoni et al reported that
it was effective in terminating attacks of angioedema.15 Bork
and Witzke also reported that the German preparation was
effective in terminating an attack of HAE.16
DEVELOPMENT OF THE CURRENTLY USED C1
INHIBITOR PREPARATIONS
In 1980, the importance of blood transfusion in trans-
mitting the newly discovered disease AIDS became clear.
The American Red Cross turned its attention to developing
procedures to make the blood supply safe, and they prepared
no further batches of C1 inhibitor. However, both the Dutch
Red Cross and Behring continued to prepare batches of C1
inhibitor for therapeutic purposes. The manufacturing arm of
the Dutch Red Cross was merged into the company Sanquin
in 2003. In 1989, heat treatment was added to the preparation
of this product, and now nanofiltration has also been added as
an extra step to ensure the absence of contaminating viruses.
The Behring product was first licensed as a unpasteurized
product in Germany in 1979 and as a pasteurized product in
1985. Thus, these 2 products are available in Europe and have
been used in patients for decades and, since the introduction
of further purification steps 2 decades ago, have not been
noted to transmit any infectious agents. The purification
procedure in both cases is designed to remove viral contam-
inants. Some years after the initial reports of successful
therapy, the Austrian company Immuno, another supplier of
gamma globulin, also began to prepare a C1 inhibitor and to
make it available in Europe. Waytes et al examined this
preparation in a double-blind study reported in 1996 and
demonstrated that it was effective for both prophylaxis and
acute treatment of angioedema attacks17; however, this prod-
uct is no longer available. Many subsequent reports have
testified to the efficacy of the European preparations. In
particular, Bork and colleagues have published extensively
on the effect of the Behring preparation in terminating acute
attack.18,19 Because prevention using attenuated androgens
was less common in Germany, an enormous number of
attacks were treated. For example, Bork et al reported the
effect of C1 inhibitor on symptoms in thousands of HAE
abdominal attacks. Many patients began to recover at about
30 minutes, and by 1 hour after treatment began most patients
were well on the road to recovery.19
INTRODUCTION OF C1 INHIBITOR INTO THE
AMERICAN MARKET
Several years ago, Behring and Sanquin made the
decision to bring their European plasma-derived products to
the United States. Over the years the original Behring Com-
pany was first divided and then acquired by a number of
companies, and now it is part of the larger company CSL
Behring. The pharmaceutical company Lev was organized in
the United States to test and bring to market the Sanquin
product. More recently, Lev was acquired by Viropharma.
RECOMBINANT C1 INHIBITOR
A new approach for the development of a human C1
inhibitor for treatment of HAE attacks was developed by a
second Dutch company, Pharming.20 This company pio-
neered the concept of isolating the human gene for a plasma
protein and fusing it to a bovine casein promoter. The new
gene was transduced into rabbits, and the animals secrete the
human gene product in their milk after pregnancy and deliv-
ery. The human protein is then isolated from the milk. This
company is in the late stages of testing their product, called
Rhucin, in treatment of HAE attacks.21
TESTING OF THE NEW PREPARATIONS
A series of double-blind studies of treatment of acute
attacks were initiated in the United States to fulfill Food and
Drug Administration (FDA) requirements. The studies per-
formed had much in common. All were placebo-controlled
trials, with each subject receiving one dose of either drug or
placebo. All patients had a preliminary screening visit at
which the diagnosis was confirmed. Patients must have had
low actual or functional amounts of plasma C1 inhibitor and
low C4 with a normal C1q. There were also details that
differed between the studies. For example, the type of attack
acceptable for the treatment protocol varied from study to
study: some allowed peripheral edema attacks, but some did
not, and some allowed facial attacks, but some did not. For
some studies, the FDA allowed C1 inhibitor to be used as the
rescue medication. In all studies the C1 inhibitor was admin-
istered intravenously. The only prophylaxis trial had a cross-
over design, as discussed below. The Behring study examined
responses to abdominal and facial attacks, and the Lev study
examined responses to abdominal, facial, and genital attacks. In
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the Lev study, the product, now called Cinryze, was used at
1000 units per patient with the possibility of the dose being
repeated if the patient did not respond.22 In the Behring study,
the product, now known as Berinert, was used at either 10 or 20
units/kg.23 In the Pharming study the product was used at 50 or
100 units/kg21; a higher dose was used because the recombinant
protein has a much shorter half-life in the circulation than the
plasma-derived protein. This is presumably because the rabbit
glycosylates proteins differently from humans, and the C1 in-
hibitor is a heavily glycosylated protein.
All 3 preparations of C1 inhibitor seem to be effective
in terminating attacks of angioedema (Fig. 1). Response is
dose-dependent, and it is likely that small differences are
determined by differences in the dose administered and the
severity and type of attack. Dose-finding studies were con-
ducted by Pharming (personal communication) and CSL
Behring.23 Patients with moderate disease started to recover
in a mean of about 9 hours with placebo and recovered in
about 5 hours when given C1 inhibitor. CSL Behring found
that 20 units/kg Berinert, not 10 units/kg, was significantly
effective in terminating attacks. Although fewer patients in
this group were studied, with severe disease the difference
was even more striking with severe attacks, which showed
relief in 12 hours with placebo and in 2 hours with C1
inhibitor. Patients responded to both the 50 and 100 unit/kg
dose of Rhucin. In general, abdominal and throat attacks
responded much more rapidly than peripheral attacks. This
may be a reflection of the fact that resorption of peripheral
edema is slow. The amount of edema that it takes to com-
promise the airway is small and the amount of edema that it
takes to stretch the gut mucosa is relatively small or relatively
easily absorbed in this area of high vascularity. In earlier studies,
clear responses were seen at 30 minutes, but in no case did the
agent lead to complete recovery in this time frame.19 All the
patients receiving placebo also recovered; HAE is a self-limited
disease and in all cases attacks resolve spontaneously.1,2 Part of
the speed of response is determined by the stage of attack when
the patient is treated. If the patient is treated early in an attack,
resolution may be quick. If he or she is at the peak of the attack,
resolution may occur more slowly. If the patient has started
to recover and is no longer generating bradykinin, the recovery
may be rapid. There is no biochemical test that allows the
physician to grade the severity of an angioedema attack or to
determine whether an attack is becoming more severe or is in the
recovery phase, and so many of these decisions are based on
experience and judgment.
It appears that both of the plasma-derived products,
Cinryze and Berinert, are effective in acute therapy. The
Behring product was approved by the FDA for treatment of
acute attacks of HAE in October 2009. The recombinant
product is reported to be effective but has not yet been
approved for therapy.
PROPHYLAXIS OF ATTACKS
Perhaps 20% of patients have attacks that are suffi-
ciently frequent or sufficiently severe that prophylaxis is
needed. As noted above, the drugs that have been tradition-
ally used for prophylaxis are not suitable in all situations and
are associated with side effects that in some patients may be
intolerable. In October 2008, the C1 inhibitor preparation
Cinryze (Viropharma) was approved by the FDA for prophy-
laxis against HAE angioedema attacks. Approval followed a
double-blind study that had a crossover design.22 Patients
received 1000 units of Cinryze or an equal volume of placebo
as an intravenous infusion 2 times per week. If the patient’s
symptoms were not controlled on 2 infusions per week, a
third infusion of Cinryze as open-label treatment was permit-
ted. After 12 weeks of treatment with drug or placebo, there
was a crossover so that patients receiving drug were switched
to placebo and patients on placebo were switched to drug.
The number, location, duration, and severity of attacks were
FIGURE 1. Two plasma-derived C1 inhibitor preparations,
Cinryze (A) and Berinert (C), and a recombinant protein,
Rhucin (B), provide faster symptom relief for acute HAE at-
tacks than placebo. Reprinted with permission from (A) New
England Journal of Medicine,22, (B) Pharming Group NV, (C)
Journal of Allergy and Clinical Immunology.23
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recorded, as was the number of times that rescue medication
was administered. The results were clear cut: on all of these
parameters patients did better on drug, and the results were
statistically highly significant. Most patients had fewer at-
tacks, although attacks were not eliminated altogether, but in
some patients the attack frequency did decrease to zero. One
patient had a markedly increased frequency of attacks on
Cinryze compared with placebo. These results point out
several things. In none of these studies did the amount of drug
given lead to complete normalization of C1 inhibitor levels,
and it seems reasonable to expect that in some patients attacks
may continue. It had previously been noted before that there
is no relationship between C1 inhibitor levels and the inci-
dence or severity of attacks.1 Patients with relatively high
levels of C1 inhibitor may have severe and frequent attacks,
and patients with relatively low levels may have mild disease.
Because the level of bradykinin is determined not only by the
rate of generation of the peptide but also by its rate of
degradation, it is reasonable to hypothesize, but has not been
shown experimentally, that differences in the rate of brady-
kinin degradation may explain this finding. Psychologic fac-
tors also have a marked influence on the frequency and
severity of attacks.22 The individual with increased attack
frequency had a series of major personal problems during the
12-week period when she was receiving Cinryze. During the
period when she was receiving placebo her life situation was
much improved and her attack frequency was much lower.
ADVANTAGES AND DISADVANTAGES OF THE
VARIOUS AGENTS
There are theoretical problems with all products. The
plasma products carry some risk of infection. Hepatitis was
transmitted by plasma-purified C1 inhibitor in the very early
days of its use, but with the introduction of more highly
refined purification and pasteurization techniques there have
been no cases of infectious disease transmission by these
agents for decades, and they are used extensively in Europe.
Plasma-derived inhibitors have the advantage that because
all patients are heterozygous for deficient C1 inhibitor
function, they have one normal gene producing normal
secreted protein, and allergy to the administered product is
unlikely unless it is modified during the purification. Fur-
thermore, because this is the normal physiologic protein, it
is expected to work in the normal way to restore patients
to physiologic balance.
Recombinant C1 inhibitor carries less risk of infection,
although rabbits do have some retroviruses. However, glyco-
sylation of the recombinant protein differs from that of the
normal C1 inhibitor, resulting in a shorter half-life. As a
result, it is unlikely to be of use in prophylaxis. Because of
the difference in sugars, there is some risk of allergy; al-
though some allergy has been noted to rabbit proteins, the
author is not aware of any allergy to the purified human C1
inhibitor. Because it is not a serum product, in theory the
supply is limitless. All of the reported testing has used
intravenous administration and only intravenous products are
FDA-approved. This limits self-administration and is there-
fore inconvenient for the patient.
COST OF THE NEW THERAPIES FOR
HEREDITARY ANGIOEDEMA
HAE has been designated an “Orphan Disease”, mean-
ing that there are so few patients that a drug manufacturer is
unlikely to see the development of therapy as profitable. For
that reason the U.S. Congress some years ago gave manufac-
turers an incentive to develop drugs for this group of diseases
by providing for 7 years of exclusivity; that is, the develop-
ment of new effective therapy for an Orphan Disease guar-
antees the developers that no other manufacturer will be able
to market the same product for 7 years. This has led directly
to an effort to have new drugs approved for the treatment of
HAE for the American market. Interestingly, multiple ap-
proaches to this problem have led to the almost simultaneous
development of effective agents. Development and testing of
drugs is expensive and the developers want to assure their
investors of a profit. As is often the case with new drugs
developed through the Orphan Disease program, the drugs
are expensive. Thus far, we know the cost of the plasma-
derived C1 inhibitor products and of Ecallantide. All are
marketed at well over $1000 dollars a dose and are far more
expensive than danazol, but all seem to have a better safety
profile. With so many new effective agents on the market, it
is not clear how pricing will proceed in the future.
CONCLUSIONS
The development of C1 inhibitor prophylaxis and ther-
apy for acute treatment represents an enormous milestone in
the history of HAE treatment. For the first time, Americans
have drugs available that clearly will terminate attacks. Fur-
thermore, there is now effective prophylactic therapy as well.
It is likely that some patients will continue to take the
androgens for cost reasons and because they are relatively
low in toxicity. Clearly, the toxicity profile of the new agents
is preferable. Nevertheless, pregnant women and children
have therapeutic alternatives that were not available in this
country in the past, and their lives will be greatly improved.
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